<a href="https://laohu8.com/S/CKDXF">Opthea Limited</a> Secures A$10.8 Million Australian R&D Tax Incentive to Advance Sozinibercept Development
Opthea Limited (ASX/NASDAQ: OPT) has announced the receipt of an A$10.8 million (US$7.2 million) research and development (R&D) tax incentive from the Australian Taxation Office. The incentive, awarded under the Australian Federal Government's R&D Tax Incentive program, supports eligible R&D expenditure for the 2024/2025 financial year, including both Australian and overseas costs related to the development of Opthea's lead candidate, sozinibercept. The funding is exclusive to Opthea Limited and is designed to encourage innovation and advance the company's clinical pipeline. Opthea's Executive Chairman, Jeremy Levin, highlighted the importance of the program in supporting the company's strategic initiatives and reaffirmed a commitment to fiscal discipline while advancing therapeutic development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opthea Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-230839), on October 06, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。